{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001429260","name":"Fortress Biotech, Inc.","summary":"Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing drug assets across subsidiary and partner companies. It markets branded dermatology products through Journey Medical Corporation (Nasdaq: DERM) and develops pipeline assets including Triplex (CMV vaccine), CUTX-101/ZYCUBO (Menkes disease), and oncology candidates. Fortress generates revenue through product sales, equity holdings, royalties, and dividends from its network of public and private subsidiaries.","people":[],"products":[{"name":"Emrosi (Minocycline HCl Extended-Release Capsules, 40mg)","type":"service","description":"FDA-approved oral treatment for inflammatory lesions of rosacea in adults, launched March 2025."},{"name":"UNLOXCYT (cosibelimab-ipdl)","type":"service","description":"FDA-approved PD-L1 blocking antibody for metastatic or locally advanced cutaneous squamous cell carcinoma."},{"name":"ZYCUBO (copper histidinate injection, CUTX-101)","type":"service","description":"FDA-approved treatment for pediatric patients with Menkes disease, approved January 2026."},{"name":"Qbrexza","type":"service","description":"Medicated cloth towelette for treatment of primary axillary hyperhidrosis."},{"name":"Accutane","type":"service","description":"Oral isotretinoin for treatment of severe recalcitrant nodular acne."},{"name":"Amzeeq (minocycline topical foam, 4%)","type":"service","description":"Topical minocycline for inflammatory lesions of moderate to severe acne vulgaris."},{"name":"Zilxi (minocycline topical foam, 1.5%)","type":"service","description":"Topical minocycline treatment for inflammatory lesions of rosacea in adults."},{"name":"Exelderm Cream and Solution","type":"service","description":"Broad-spectrum antifungal for topical use."},{"name":"Targadox","type":"service","description":"Oral doxycycline for adjunctive therapy for severe acne."},{"name":"Luxamend","type":"service","description":"Water-based emulsion for moist healing environment for wounds, burns, and dermal ulcers."},{"name":"Triplex (CMV vaccine)","type":"service","description":"Recombinant Modified Vaccinia Ankara viral vector vaccine targeting CMV, in multiple Phase 2 trials."},{"name":"ATX-04 (clenbuterol)","type":"service","description":"Licensed from Duke University for development in lysosomal storage diseases."}],"partnerships":[{"partner_name":"Sun Pharmaceutical Industries Limited","partnership_type":"strategic","description":"Acquired Checkpoint Therapeutics in May 2025; Fortress receives royalties on UNLOXCYT net sales.","start_date":null},{"partner_name":"Sentynl Therapeutics, Inc.","partnership_type":"licensing","description":"Acquired CUTX-101 NDA assets from Cyprium; obligated to commercialize ZYCUBO with milestone and royalty payments to Cyprium.","start_date":null},{"partner_name":"AstraZeneca plc (successor to Alexion Pharmaceuticals)","partnership_type":"strategic","description":"Strategic partnership with a Fortress subsidiary.","start_date":null},{"partner_name":"Axsome Therapeutics, Inc.","partnership_type":"strategic","description":"Acquired Baergic Bio from Avenue Therapeutics in November 2025.","start_date":null},{"partner_name":"City of Hope National Medical Center","partnership_type":"licensing","description":"Helocyte holds exclusive worldwide license to Triplex CMV vaccine from COH.","start_date":null},{"partner_name":"Dana-Farber Cancer Institute","partnership_type":"development","description":"Arrangement to identify and evaluate promising product candidates.","start_date":null},{"partner_name":"Nationwide Children's Hospital","partnership_type":"development","description":"Arrangement to identify and evaluate promising product candidates.","start_date":null},{"partner_name":"Columbia University","partnership_type":"development","description":"Arrangement to identify and evaluate promising product candidates.","start_date":null},{"partner_name":"University of Pennsylvania","partnership_type":"development","description":"Arrangement to identify and evaluate promising product candidates.","start_date":null},{"partner_name":"Dr. Reddy's Laboratories, Ltd.","partnership_type":"development","description":"Arrangement executed in partnership for product development or licensing.","start_date":null},{"partner_name":"Duke University","partnership_type":"licensing","description":"Avenue obtained exclusive worldwide license for ATX-04 (clenbuterol) for lysosomal storage diseases in February 2026.","start_date":null},{"partner_name":"National Institute of Allergy and Infectious Diseases (NIH)","partnership_type":"development","description":"Grant funding over $20 million for Triplex Phase 2 liver transplant trial.","start_date":null},{"partner_name":"National Cancer Institute (NCI)","partnership_type":"development","description":"Grant funding for Triplex Phase 2 stem cell transplant trial.","start_date":null}],"affiliations":[],"origin":{"leaf":"c6797a6d5235ff9eaeebb406031906be4a147fa483b66dfbec7867ffb6a96d20","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"fa4e5e4db6f02e9b97c0c025224eaebaa8f6ef574abaa70b6e083f6949751ff0","parent":"9359a28af6bf3c90c0872afbe90891a7f34b45cf55060c167698c557820ff61f","source":"0001104659-26-037874","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":110,"hourly_limit":500,"remaining":390,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}